Brigacent 90 mg (Tablet)
Unit Price: ৳ 1,000.00 (1 x 7: ৳ 7,000.00)
Strip Price: ৳ 7,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Brigatinib |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Indications
- Treatment of ALK-positive metastatic Non-small cell lung cancer
- Patients intolerant to Crizotinib
Pharmacology
- Tyrosine kinase inhibitor
- Activity against ALK, ROS1, IGF-1R, FLT-3, EGFR
- Inhibition of autophosphorylation of ALK
- Metabolism by CYP2C8 and CYP3A4
- Excretion in feces and urine
Dosage & Administration
- Initial dose at 90 mg orally once daily for 7 days
- If tolerated, increase to 180 mg orally once daily
- Can be taken with or without food
- Tablets should be swallowed whole
Interactions
- Strong CYP3A inhibitors increase plasma concentrations
- Strong CYP3A inducers decrease plasma concentrations
- Brigacent induces CYP3A and may decrease concentrations of CYP3A substrates
Contraindications
- Known hypersensitivity to Brigatinib or any other components
Side Effects
- Interstitial Lung Disease (ILD)/Pneumonitis
- Hypertension
- Bradycardia
- Visual Disturbance
- Creatine Phosphokinase (CPK) Elevation
- Pancreatic Enzyme Elevation
- Hyperglycemia
Pregnancy & Lactation
- No clinical data on use in pregnant women
- Lactating women should not breastfeed during treatment
- Females of reproductive potential should use effective non-hormonal contraception
Precautions & Warnings
- Severe pulmonary adverse reactions
- Blood pressure monitoring and control
- Monitoring for visual disturbances
- Monitoring and management of CPK and pancreatic enzyme elevation
- Assessment and management of hyperglycemia
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Keep below 30°C temperature
- Away from light & moisture
- Keep out of the reach of children